Metastatic breast cancer treatment

PERJETA, along with Herceptin® (trastuzumab) and docetaxel, is a first-line treatment for HER2+ breast cancer that has spread to other parts of the body (metastasized). This will be given to you if you have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer (first line).

Keep in mind that metastatic breast cancer is treatable but not curable. A goal of metastatic breast cancer treatment is to help control cancer growth.

Who can receive PERJETA

PERJETA and Herceptin-based therapy may be an appropriate option for people with HER2+ metastatic breast cancer that:

  • Has spread to other parts of the body (metastatic), and
  • Has NOT been treated with traditional chemotherapy or HER2-targeted treatments before for metastatic breast cancer

How PERJETA + Herceptin-based therapy may help

Side effects may occur with PERJETA

What are the most serious side effects of PERJETA?

Receiving PERJETA during pregnancy can result in the death of an unborn baby and birth defects.

PERJETA may cause heart problems, including those without symptoms (such as reduced heart function) and those with symptoms (such as congestive heart failure).

What are other possible serious side effects of PERJETA?
PERJETA should not be used in patients who are allergic to pertuzumab or to any of the ingredients in PERJETA. Possible serious and sometimes fatal side effects of PERJETA include infusion-related reactions and severe allergic reactions (hypersensitivity reactions/anaphylaxis).

See additional Important Safety Information below.

Enroll in a free patient support program designed specifically for people living with HER2+ breast cancer. 

Discover information and resources to help you have an informative conversation with your doctor.